Clinical significance of the determination of antibodies to thrombospondin type 1 containing domain 7A (THSD7A) in membranous nephropathy
- 作者: Kakhsurueva P.1, Kamyshova E.1, Bobkova I.1, Stavrovskaya E.1, Rudenko T.1, Andreeva E.1
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 95, 编号 6 (2023)
- 页面: 462-467
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/133105
- DOI: https://doi.org/10.26442/00403660.2023.06.202268
- ID: 133105
如何引用文章
全文:
详细
Background. Membranous nephropathy (MN) is an immunocomplex glomerular disease, which is the most common cause of nephrotic syndrome in adults. Numerous studies have established that autoantibodies against the target podocyte autoantigens, including the thrombospondin type 1 domain containing 7A (THSD7A), play a leading role in the development of idiopathic MN.
Aim. To evaluate the prevalence of anti-THSD7A autoantibodies (anti-THSD7A AB) in a group of Russian patients with MN.
Materials and methods. Serum titers of anti-THSD7A AB were tested in 61 patients with biopsy-proven MN and 12 healthy controls.
Results. The prevalence of anti-THSD7A AB was not differing significantly in patients with MN and in the control group (110.9 [71.63; 210.62] and 159.25 [125.64; 231.97] pg/ml, respectively; p=0.111). When comparing subgroups of anti-PLA2R-negative patients and patients who did not receive immunosuppressive therapy with the control group, there were also no statistically significant differences in the Anti-THSD7A AB levels (p>0.05). In the MN group, 1 (1.6%) patient was anti-THSD7A-positive: a 60-year-old man with anti-PLA2R-negative MN and the presence of hormonally inactive adenomas of both adrenal glands and colon polyps (villous adenoma with focal moderate dysplasia, tubulo-villous and tubular adenoma with focal moderate severe dysplasia).
Conclusion. THSD7-associated MN is a rare variant of MN and is usually detected in PLA2R-negative patients. Screening for malignancies in THSD7A-positive MN patients is proposed.
作者简介
Patimat Kakhsurueva
Sechenov First Moscow State Medical University (Sechenov University)
Email: kamyshova_e_s@staff.sechenov.ru
ORCID iD: 0009-0002-6138-870X
аспирант каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowElena Kamyshova
Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: kamyshova_e_s@staff.sechenov.ru
ORCID iD: 0000-0002-1823-0125
канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowIrina Bobkova
Sechenov First Moscow State Medical University (Sechenov University)
Email: kamyshova_e_s@staff.sechenov.ru
ORCID iD: 0000-0002-8007-5680
д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowEkaterina Stavrovskaya
Sechenov First Moscow State Medical University (Sechenov University)
Email: kamyshova_e_s@staff.sechenov.ru
ORCID iD: 0000-0001-6381-2186
канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowTatiana Rudenko
Sechenov First Moscow State Medical University (Sechenov University)
Email: kamyshova_e_s@staff.sechenov.ru
ORCID iD: 0000-0002-1296-4494
канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowElena Andreeva
Sechenov First Moscow State Medical University (Sechenov University)
Email: kamyshova_e_s@staff.sechenov.ru
канд. мед. наук, врач-нефролог клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3
俄罗斯联邦, Moscow参考
- Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002;346(26):2053-60. doi: 10.1056/NEJMoa012895
- Madaio MP, Salant DJ, Cohen AJ, et al. Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int. 1983;23(3):498-505. doi: 10.1038/ki.1983.47
- Beck LH Jr., Bonegio RG, Lambeau G, et al. M-Type Phospholipase A2 Receptor as Target Antigen in IdiopathicMembranous Nephropathy. N Engl J Med. 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457
- Qin W, Beck LH Jr., Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137-43. doi: 10.1681/ASN.2010090967
- Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526-32. doi: 10.1093/ndt/gfr247
- Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol. 2015;19(4):653-60. doi: 10.1007/s10157-014-1054-2
- Hayashi N, Akiyama S, Okuyama H, et al. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2015;19(5):797-803. doi: 10.1007/s10157-014-1064-0
- Hara S, Goto S, Kamiura N, et al. Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype. Virchows Arch. 2015;467(1):87-94. doi: 10.1007/s00428-015-1754-3
- Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95:429-38. doi: 10.1016/j.kint.2018.10.021
- De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421-30. doi: 10.1681/ASN.2016070776
- Hofstra JM, Beck LH Jr., Beck DM, et al. Anti-Phospholipase A(2) Receptor Antibodies Correlate With Clinical Status in Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-91. doi: 10.2215/CJN.07210810
- Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386-92. doi: 10.2215/CJN.10471013
- Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58. doi: 10.1681/ASN.2014070640
- Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients With Idiopathic Membranous Nephropathy. Kidney Int. 2013;83(5):940-8. doi: 10.1038/ki.2012.486
- Quintana LF, Blasco M, Seras M, et al. Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. Transplantation. 2015;99(8):1709-14. doi: 10.1097/TP.0000000000000630
- Tomas NM, Beck LH Jr., Meyer-Schwesinger C, et al. Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. N Engl J Med. 2014;371(24):2277-87. doi: 10.1056/NEJMoa1409354
- Hoxha E, Beck LH Jr., Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):520-31. doi: 10.1681/ASN.2016010050
- Wang J, Cui Z, Lu J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642-51. doi: 10.2215/CJN.01460217
- Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016;126(7):2519-32. doi: 10.1172/JCI85265
- Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. J Am Soc Nephrol. 2017;28(11):3262-77. doi: 10.1681/ASN.2017010030
- Hoxha E, Wiech T, Stahl PR, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med. 2016;374(20):1995-6. doi: 10.1056/NEJMc1511702
- Liu Y, Zheng S, Ma C, et al. Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy. Glob Chall. 2020;4(11):1900099. doi: 10.1002/gch2.201900099
- Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019;95(3):666-79. doi: 10.1016/j.kint.2018.10.024
- Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-22. doi: 10.1038/modpathol.2017.163
- Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735-43. doi: 10.1007/s00428-019-02558-0
- Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306-13. doi: 10.1080/0886022X.2018.1456457
- Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014;40(1):29-35. doi: 10.1159/000364782